As in the case with ALK-rearranged NSCLC, concurrent mutations such as TP53 may also play a role on differential responses to targeted therapy [28] and further exploration in the space of fusion partners and concurrent mutations in ROS1+ NSCLC is eagerly awaited. The gene discussed is ALK; the disease is non-small cell lung carcinoma.